## Massimo G Roncalli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6176955/publications.pdf

Version: 2024-02-01

20759 23472 13,557 162 60 111 citations h-index g-index papers 165 165 165 16965 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Digital Pathology During the COVID-19 Outbreak in Italy: Survey Study. Journal of Medical Internet Research, 2021, 23, e24266.	2.1	4
2	Hepatocellular carcinoma: a clinical and pathological overview. Pathologica, 2021, 113, 203-217.	1.3	30
3	Development of a Deep-Learning Pipeline to Recognize and Characterize Macrophages in Colo-Rectal Liver Metastasis. Cancers, 2021, 13, 3313.	1.7	8
4	Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma. Hepatology, 2020, 71, 183-195.	3.6	119
5	Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. Liver Cancer, 2020, 9, 15-27.	4.2	56
6	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. Clinical Cancer Research, 2020, 26, 4381-4389.	3.2	44
7	Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis. Journal of Experimental Medicine, 2020, 217, .	4.2	99
8	Retrospective analysis of an alternative immuno-score in clinical management of patients with pT2 urothelial carcinoma Journal of Clinical Oncology, 2020, 38, e17038-e17038.	0.8	0
9	The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication Journal of Clinical Oncology, 2020, 38, e17037-e17037.	0.8	O
10	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. American Journal of Pathology, 2019, 189, 2090-2101.	1.9	17
11	Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. Journal of Gastrointestinal Surgery, 2019, 23, 2216-2224.	0.9	32
12	cHCCâ€CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 2018, 68, 113-126.	3.6	244
13	A Large Set of miRNAs Is Dysregulated from the Earliest Steps of Human Hepatocellular Carcinoma Development. American Journal of Pathology, 2018, 188, 785-794.	1.9	15
14	Filamin A expression predicts early recurrence of hepatocellular carcinoma after hepatectomy. Liver International, 2018, 38, 303-311.	1.9	9
15	High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. Laboratory Investigation, 2018, 98, 95-105.	1.7	41
16	Phenotypic and molecular changes in noduleâ€inâ€nodule hepatocellular carcinoma with pathogenetic implications. Histopathology, 2018, 73, 601-611.	1.6	11
17	The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. Frontiers in Oncology, 2018, 8, 181.	1.3	19
18	Premalignant and Early Malignant Hepatocellular Lesions in Chronic Hepatitis/Cirrhosis. , 2018, , 487-505.		1

#	Article	IF	CITATIONS
19	Transarterial Therapies for Hepatocellular Carcinoma. Liver Cancer, 2017, 6, 27-33.	4.2	44
20	A phosphokinomeâ€based screen uncovers new drug synergies for cancer driven by liverâ€specific gain of nononcogenic receptor tyrosine kinases. Hepatology, 2017, 66, 1644-1661.	3.6	15
21	Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival. Journal of Gastrointestinal Surgery, 2017, 21, 1226-1236.	0.9	69
22	Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer. Oncolmmunology, 2017, 6, e1333215.	2.1	56
23	CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: A retrospective multicentric validation study. Digestive and Liver Disease, 2017, 49, 434-439.	0.4	9
24	Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. Oncolmmunology, 2017, 6, e1342918.	2.1	90
25	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 2017, 20, 428-437.	2.7	5
26	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. Journal of Hepatology, 2017, 66, 102-115.	1.8	130
27	Tissue Biomarkers in Hepatocellular Tumors: Which, When, and How. Frontiers in Medicine, 2017, 4, 10.	1.2	21
28	Progressive Enrichment of Stemness Features and Tumor Stromal Alterations in Multistep Hepatocarcinogenesis. PLoS ONE, 2017, 12, e0170465.	1.1	12
29	Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. Clinical and Molecular Hepatology, 2016, 22, 199-211.	4.5	48
30	Occurrence and significance of tumorâ€associated neutrophils in patients with colorectal cancer. International Journal of Cancer, 2016, 139, 446-456.	2.3	141
31	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Research, 2016, 18, 121.	2.2	89
32	Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase. Journal of Experimental and Clinical Cancer Research, 2016, 35, 193.	3.5	7
33	Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. International Journal of Cancer, 2016, 138, 983-991.	2.3	49
34	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1954-1961.	3.3	122
35	Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma. Modern Pathology, 2016, 29, 283-292.	2.9	43
36	The Fractalkine-Receptor Axis Improves Human Colorectal Cancer Prognosis by Limiting Tumor Metastatic Dissemination. Journal of Immunology, 2016, 196, 902-914.	0.4	35

#	Article	IF	CITATIONS
37	Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncolmmunology, 2016, 5, e1085147.	2.1	169
38	Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. Journal of Hepatology, 2016, 64, 87-93.	1.8	40
39	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS ONE, 2016, 11, e0159612.	1.1	23
40	Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma. Oncotarget, 2016, 7, 54650-54661.	0.8	63
41	Effect of intratumoral CD3+ and NKp46+ cells on tumor progression in resected colorectal liver metastases treated with neoadjuvant chemotherapy Journal of Clinical Oncology, 2016, 34, 281-281.	0.8	0
42	Unclassified Renal Cell Carcinoma With Medullary Phenotype Versus Renal Medullary Carcinoma: Lessons From Diagnosis in an Italian Man Found to Harbor Sickle Cell Trait. Urology Case Reports, 2015, 3, 215-218.	0.1	10
43	An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab. International Journal of Biological Markers, 2015, 30, 73-80.	0.7	5
44	One-Step Nucleic Acid Amplification in Breast Cancer Sentinel Lymph Node: A Single Institutional Experience and a Short Review. Frontiers in Medicine, 2015, 2, 37.	1.2	5
45	PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer. Cell, 2015, 160, 700-714.	13.5	334
46	Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1166-1175.	2.5	302
47	The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. Digestive and Liver Disease, 2015, 47, 432-435.	0.4	26
48	TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver International, 2015, 35, 2466-2473.	1.9	24
49	MicroRNAâ€425â€3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver International, 2015, 35, 1077-1086.	1.9	68
50	Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease. PLoS ONE, 2014, 9, e95303.	1.1	52
51	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology, 2014, 60, 1983-1992.	3.6	268
52	YAP activation is an early event and a potential therapeutic target in liver cancer development. Journal of Hepatology, 2014, 61, 1088-1096.	1.8	191
53	Nested stromal-epithelial tumour of the liver: An unusual liver entity. World Journal of Hepatology, 2014, 6, 155.	0.8	15
54	Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer, 2013, 119, 266-276.	2.0	34

#	Article	IF	Citations
55	Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1179-1187.	1.2	34
56	Presence of Twist1-Positive Neoplastic Cells in the Stroma ofÂChromosome-Unstable Colorectal Tumors. Gastroenterology, 2013, 145, 647-657.e15.	0.6	49
57	Advanced precancerous lesions in the liver. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 269-284.	1.0	46
58	Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. European Journal of Cancer, 2013, 49, 989-998.	1.3	12
59	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. Digestive and Liver Disease, 2013, 45, 43-49.	0.4	23
60	High efficacy of endoscopic submucosal dissection for rectal laterally spreading tumors larger than 3 cm. Gastrointestinal Endoscopy, 2013, 77, 96-101.	0.5	80
61	Multiple focal nodular hyperplasias induced by oxaliplatin-based chemotherapy. World Journal of Hepatology, 2013, 5, 340.	0.8	30
62	p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 520-527.	0.5	19
63	MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver International, 2012, 32, 772-782.	1.9	89
64	Identifying and Targeting <i>ROS1</i> Gene Fusions in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 4570-4579.	3.2	405
65	Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death and Disease, 2012, 3, e351-e351.	2.7	63
66	Role of the stromal-derived factor-1 (SDF-1)–CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. Journal of Hepatology, 2012, 57, 813-820.	1.8	82
67	The "farmer―pathologist: a midsummer night's dream. Human Pathology, 2012, 43, 615-616.	1.1	0
68	Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2012, 7, e46002.	1.1	63
69	A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology, 2012, 55, 1776-1786.	3.6	127
70	Cardiac hibernoma: a case report. Histopathology, 2012, 61, 985-987.	1.6	7
71	Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin. Clinical Cancer Research, 2011, 17, 2581-2590.	3.2	94
72	Liver precancerous lesions and hepatocellular carcinoma: The histology report. Digestive and Liver Disease, 2011, 43, S361-S372.	0.4	52

#	Article	IF	CITATIONS
73	Surgical Procedures in the DANTE Trial, A Randomized Study of Lung Cancer Early Detection with Spiral Computed Tomography: Comparative Analysis in the Screening and Control Arm. Journal of Thoracic Oncology, 2011, 6, 327-335.	0.5	46
74	The critical role of agrin in the hematopoietic stem cell niche. Blood, 2011, 118, 2733-2742.	0.6	47
75	Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death and Differentiation, 2011, 18, 1608-1616.	5.0	57
76	Modulation of human Tâ€cell functions by reactive nitrogen species. European Journal of Immunology, 2011, 41, 1843-1849.	1.6	54
77	Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology, 2011, 53, 1549-1557.	3.6	77
78	The <i>HOX</i> gene network in hepatocellular carcinoma. International Journal of Cancer, 2011, 129, 2577-2587.	2.3	60
79	Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Science Translational Medicine, 2011, 3, 99ra86.	5.8	543
80	Premalignant Hepatocellular Lesions. , 2011, , 457-472.		0
81	Expression and Mutational Status of c-kit in Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2010, 5, 1447-1453.	0.5	61
82	Cracking Spaces in Hashimoto Thyroiditis Are Lymphatic and Prelymphatic Vessels. American Journal of Surgical Pathology, 2010, 34, 1857-1861.	2.1	6
83	Radiological estimation of size in colorectal liver metastases: is it reliable? Comparison with post-resectional measurements. Updates in Surgery, 2010, 62, 21-26.	0.9	14
84	Insulinâ€like growth factorâ€1 receptor and phosphorylated AKTâ€serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer, 2010, 116, 4686-4695.	2.0	59
85	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation. Hepatology, 2010, 52, 1723-1730.	3.6	67
86	Prostatic Stromal Tumor with Fatal Outcome in a Young Man: Histopathological and Immunohistochemical Case Presentation. Rare Tumors, 2010, 2, rt.2010.e57.	0.3	21
87	Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness. Molecular Medicine, 2010, 16, 102-115.	1.9	69
88	Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Annals of Oncology, 2010, 21, 562-567.	0.6	70
89	Hepatic Rosai-Dorfman Disease With Coincidental Lymphoma: Report of a Case. International Journal of Surgical Pathology, 2010, 18, 540-543.	0.4	10
90	Histopathological classification of hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, S228-S234.	0.4	70

#	Article	IF	CITATIONS
91	Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. European Journal of Cancer, 2010, 46, 3383-3392.	1.3	55
92	The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut, 2010, 59, 197-206.	6.1	138
93	M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro. Journal of Immunology, 2009, 182, 4415-4422.	0.4	227
94	Cell Discohesion and Multifocality of Carcinoma In situ of the Bladder: New Insight From the Adhesion Molecule Profile (e-Cadherin, Ep-CAM, and MUC1). International Journal of Surgical Pathology, 2009, 17, 99-106.	0.4	17
95	A Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 445-453.	2.5	365
96	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Annals of Oncology, 2009, 20, 298-304.	0.6	286
97	Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer, 2009, 9, 125.	1.1	130
98	Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology, 2009, 49, 658-664.	3 <b>.</b> 6	722
99	Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology, 2009, 50, 752-762.	3.6	68
100	Increased <i>MET</i> Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2009, 27, 1667-1674.	0.8	530
101	The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. Journal of Hepatology, 2009, 50, 746-754.	1.8	280
102	Identification of Potential Therapeutic Targets in Malignant Mesothelioma Using Cell-Cycle Gene Expression Analysis. American Journal of Pathology, 2009, 174, 762-770.	1.9	48
103	CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncology, The, 2009, 10, 877-884.	5.1	226
104	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Annals of Oncology, 2008, 19, 717-723.	0.6	243
105	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. British Journal of Cancer, 2008, 99, 83-89.	2.9	167
106	Gene methylation in pleural mesothelioma: Correlations with clinico-pathological features and patient's follow-up. Lung Cancer, 2008, 59, 369-376.	0.9	42
107	Lung cancer screening with spiral CT. Lung Cancer, 2008, 59, 355-363.	0.9	179
108	Toker cells of the breast. Morphological and immunohistochemical characterization of 40 cases. Human Pathology, 2008, 39, 1295-1300.	1.1	58

#	Article	IF	Citations
109	Non-Hormone-Induced Mixed Epithelial and Stromal Tumor of Kidney in a Man: Description of a Rare Case. Urology, 2008, 71, 168.e7-168.e9.	0.5	5
110	Glypican 3 Expression in Human Nonneoplastic, Preneoplastic, and Neoplastic Tissues. American Journal of Clinical Pathology, 2008, 129, 899-906.	0.4	229
111	The Chemokine Receptor CX3CR1 Is Involved in the Neural Tropism and Malignant Behavior of Pancreatic Ductal Adenocarcinoma. Cancer Research, 2008, 68, 9060-9069.	0.4	153
112	Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program. Clinical Cancer Research, 2008, 14, 1913-1919.	3.2	52
113	Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of Oncology, 2008, 19, 1605-1612.	0.6	81
114	Hepatocellular dysplastic nodules. Annali Italiani Di Chirurgia, 2008, 79, 81-9.	0.1	10
115	Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer. Clinical Cancer Research, 2007, 13, 3831-3839.	3.2	221
116	Thymic Tumor With Adenoid Cystic Carcinomalike Features. American Journal of Surgical Pathology, 2007, 31, 1161-1167.	2.1	31
117	Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology, 2007, 45, 725-734.	3.6	379
118	Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology, 2007, 45, 968-976.	3.6	133
119	Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer, 2007, 109, 915-923.	2.0	124
120	Hepatocellular dysplastic nodules. Hepatology Research, 2007, 37, S125-S134.	1.8	35
121	Laparoscopic lymphatic mapping and sentinel lymph node detection in colon cancer: technical aspects and preliminary results. Surgical Endoscopy and Other Interventional Techniques, 2007, 21, 1567-1571.	1.3	29
122	Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. British Journal of Cancer, 2006, 95, 1101-1107.	2.9	73
123	Large liver cell dysplasia: A controversial entity. Journal of Hepatology, 2006, 45, 734-743.	1.8	54
124	Anatomic Location of Breast Cancer Micrometastasis in Sentinel Lymph Node Predicts Axillary Status. Annals of Surgery, 2006, 243, 706-707.	2.1	13
125	Quantitative evaluation of RASSF1Amethylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer, 2006, 6, 89.	1.1	56
126	DANTE: A RANDOMIZED STUDY ON LUNG CANCER SCREENING WITH LOW-DOSE SPIRAL CT (LDCT): END OF ACCRUAL AND PRELIMINARY RESULTS. Chest, 2006, 130, 114S.	0.4	2

#	Article	IF	Citations
127	Immunohistochemical profile and c-kit mutations in gastrointestinal stromal tumors. Pathology Research and Practice, 2005, 201, 71-81.	1.0	7
128	Contrast-Enhanced Intraoperative Ultrasonography During Hepatectomies for Colorectal Cancer Liver Metastases. Journal of Gastrointestinal Surgery, 2005, 9, 1148-1154.	0.9	83
129	Cutaneous Melanoma Metastatic to Uterine Adenomyoma: Report of a Case. International Journal of Surgical Pathology, 2005, 13, 223-225.	0.4	9
130	Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer, 2005, 48, 211-216.	0.9	38
131	Re: Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability. Journal of the National Cancer Institute, 2004, 96, 1402-1403.	3.0	30
132	Activity of a specific inhibitor, gefitinib (Iressaâ,,¢, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Annals of Oncology, 2004, 15, 33-37.	0.6	34
133	Hepatocellular nodules in cirrhosis: Focus on diagnostic criteria on liver biopsy. A Western experience. Liver Transplantation, 2004, 10, S9-S15.	1.3	61
134	Acinar cell cystadenocarcinoma of the pancreas: Report of rare case and review of the literature. Human Pathology, 2004, 35, 1568-1571.	1.1	47
135	Nucleolar hypertrophy correlates with hepatocellular carcinoma development in cirrhosis due to HBV infection. Hepatology, 2003, 37, 72-78.	3.6	34
136	Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. Journal of Hepatology, 2003, 39, 208-214.	1.8	182
137	Dante: A Randomised Trial on Early Diagnosis of Lung Cancer With Low-dose Spiral CT (LDCT); Initial Announcemen. Chest, 2003, 124, 118S.	0.4	3
138	HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clinical Cancer Research, 2003, 9, 3645-52.	3.2	81
139	Prediction of Survival in Stage I Lung Carcinoma Patients by Telomerase Function Evaluation. Laboratory Investigation, 2002, 82, 729-736.	1.7	39
140	Frameshift Mutations of Human Gastrin Receptor Gene (hGARE) in Gastrointestinal Cancers with Microsatellite Instability. Laboratory Investigation, 2002, 82, 265-271.	1.7	21
141	Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology, 2002, 36, 427-432.	3.6	108
142	Molecular disorders in transitionalys. peripheral zone prostate adenocarcinoma. International Journal of Cancer, 2001, 94, 383-389.	2.3	16
143	Contrast-enhanced doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology, 2001, 34, 1109-1112.	3.6	79
144	Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients. British Journal of Cancer, 2001, 84, 196-198.	2.9	38

#	Article	IF	Citations
145	Renal Angiomyolipoma With Epithelioid Sarcomatous Transformation and Metastases. American Journal of Surgical Pathology, 2000, 24, 889-894.	2.1	123
146	Fractional allelic loss in non–end-stage cirrhosis: Correlations with hepatocellular carcinoma development during follow-up. Hepatology, 2000, 31, 846-850.	3.6	51
147	Molecular Changes in Hepatocellular Dysplastic Nodules on Microdissected Liver Biopsies. Hepatology, 2000, 32, 942-946.	3.6	72
148	Can Large Cell Change and High Proliferative Activity Predict Hepatocellular Carcinoma in Patients With Hereditary Hemochromatosis?. American Journal of Gastroenterology, 2000, 95, 2940-2945.	0.2	6
149	The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: Implications for diagnosis and classification. Hepatology, 1999, 30, 1174-1178.	3.6	195
150	Preneoplastic cellular changes in liver. Hepatology, 1998, 28, 1435-1435.	3.6	11
151	Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. , 1998, 34, 113-120.		45
152	Ultrasonography-detected macroregenerative nodules in cirrhosis: a prospective study. Gastroenterology, 1997, 112, 1617-1623.	0.6	55
153	p53 protein accumulation and p53 gene mutation in esophageal carcinoma. , 1997, 79, 425-432.		145
154	Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: A prospective study. Gastroenterology, 1995, 108, 812-817.	0.6	219
155	Integrin common chain $\hat{l}^21$ immunoreactivity in hepatocellular carcinoma. Journal of Pathology, 1994, 172, 363-364.	2.1	0
156	Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma. Cancer, 1994, 74, 134-141.	2.0	24
157	Expression of new phenotypic markers in cholangiocarcinoma and putative precursor lesions. Journal of Surgical Oncology, 1993, 53, 173-174.	0.8	4
158	Patterns of integrin common chain $\hat{l}^21$ and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size. Journal of Pathology, 1993, 171, 5-11.	2.1	26
159	Abnormal p53 Expression in Lung Neuroendocrine Tumors Diagnostic and Prognostic Implications. Diagnostic Molecular Pathology, 1992, 1, 129-135.	2.1	39
160	Distribution of Endothelin-like Immunoreactivity and mRNA in the Developing and Adult Human Lung. American Journal of Respiratory Cell and Molecular Biology, 1991, 4, 50-58.	1.4	129
161	A morphometric study of liver cell dysplasia. Human Pathology, 1988, 19, 471-474.	1.1	39
162	Liver cell dysplasia in cirrhosis. A serologic and immunohistochemical study. Cancer, 1986, 57, 1515-1521.	2.0	32